Table 2.
Patient characteristics before and after Vitamin B6 treatment (n = 22)
| Characteristics | Before treatment | After treatment | p value | |
|---|---|---|---|---|
| Liver image | MRI-PDFF†, % | 18.7 ± 6.1 | 16.4 ± 6.4 | <0.001** |
| Magnetic resonance elastography, kPa | 2.6 ± 0.92 | 2.5 ± 0.73 | 0.26 | |
| Metabolic factors | Weight, kg | 79.4 ± 15.8 | 79.3 ± 15.5 | 0.978 |
| Body mass index, kg/m2 | 28.6 ± 4.1 | 28.4 ± 4.0 | 0.922 | |
| Systolic blood pressure, mmHg | 126.3 ± 4.4 | 124.5 ± 5.0 | 0.162 | |
| Glucose, mg/dl | 121.2 ± 29.8 | 119.8 ± 31.4 | 0.85 | |
| Insulin, µU/ml | 45.5 ± 58.2 | 45.0 ± 53.4 | 0.97 | |
| HOMA-IR‡ | 10.5 ± 11.4 | 10.3 ± 12.0 | 0.936 | |
| Hemoglobin A1c, % | 6.2 ± 1.01 | 6.2 ± 1.09 | 0.93 | |
| Liver function | Platelet counts, ×109/L | 218.1 ± 55.0 | 222.3 ± 57.9 | 0.449 |
| Alanine aminotransferase, IU/L | 93.6 ± 46.9 | 93.9 ± 46.6 | 0.976 | |
| Aspartate aminotransferase, IU/L | 60.2 ± 29.6 | 58.0 ± 24.9 | 0.753 | |
| γ-Glutamyl transferase, IU/L | 90.0 ± 51.5 | 86.5 ± 37.8 | 0.567 | |
| Alkaline phosphatase, IU/L | 230.3 ± 72.9 | 232.5 ± 67.8 | 0.768 | |
| Total bilirubin, mg/dl | 0.83 ± 0.41 | 0.75 ± 0.30 | 0.131 | |
| Lipids | Total cholesterol, mg/dl | 184.8 ± 35.4 | 193.3 ± 40.9 | 0.336 |
| Low-density lipoprotein cholesterol, mg/dl | 104.3 ± 31.4 | 110.7 ± 37.9 | 0.394 | |
| High-density lipoprotein cholesterol, mg/dl | 37.4 ± 19.4 | 42.6 ± 22.5 | 0.066 | |
| Triglyceride, mg/dl | 229.4 ± 171.4 | 206.1 ± 131.4 | 0.302 | |
| Inflammation marker | High sensitivity C-reactive protein, mg/L | 0.17 ± 0.16 | 0.12 ± 0.11 | 0.299 |
| Ferritin, ng/ml | 189.6 ± 151.5 | 171.2 ± 107.4 | 0.243 | |
| Fibrosis marker | Type IV collagen 7s, ng/ml | 5.2 ± 1.5 | 5.7 ± 1.9 | 0.020* |
| Fibrosis-4 index | 1.6 ± 1.0 | 1.6 ± 1.1 | 0.206 | |
| Renal function | Blood urea nitrogen, mg/dl | 13.7 ± 4.9 | 13.2 ± 2.8 | 0.617 |
| Creatinine, mg/dl | 0.80 ± 0.20 | 0.78 ± 0.21 | 0.164 | |
| Vitamin B6 | Pyridoxamine, ng/ml | 0.35 ± 0.24 | 0.87 ± 0.80 | 0.054 |
| Pyridoxal, ng/ml | 34.2 ± 77.2 | 224.3 ± 235.6 | <0.001*** | |
| Pyridoxine, ng/ml | 3.03 ± 0.13 | 4.61 ± 5.73 | 0.22 | |
| SF-8§ quality of life | Physical component | 48.2 ± 7.6 | 48.3 ± 6.0 | 0.972 |
| Mental component | 49.2 ± 7.7 | 49.5 ± 6.7 | 0.657 |
Data are expressed as number (%) or mean ± SD; *p<0.05, **p<0.01, ***p<0.001; †magnetic resonance imaging-based proton density fat fraction; ‡homeostasis model assessment as an index of insulin resistance; §8-Item Short-Form Health Survey.